Publication: SEOM-GEINO clinical guidelines for grade 2 gliomas (2023)
No Thumbnail Available
Identifiers
Date
2024-04-25
Authors
Vaz-Salgado, Maria Angeles
Cigarral-Garcia, Belen
Fernandez-Perez, Isaura
Jimenez-Munarriz, Beatriz
Sampedro-Domarco, Paula
Hernandez-Gonzalez, Ainhoa
Vieito-Villar, Maria
Luque-Caro, Raquel
Villamayor-Delgado, Maria Luisa
Sepulveda-Sanchez, Juan Manuel
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Springer
Metrics
Export
Abstract
The 2021 World Health Organization (WHO) classification has updated the definition of grade 2 gliomas and the presence of isocitrate dehydrogenase (IDH) mutation has been deemed the cornerstone of diagnosis. Though slow-growing and having a low proliferative index, grade 2 gliomas are incurable by surgery and complementary treatments are vital to improving prognosis. This guideline provides recommendations on the multidisciplinary treatment of grade 2 astrocytomas and oligodendrogliomas based on the best evidence available.
Description
MeSH Terms
Oligodendroglioma
Isocitrate Dehydrogenase
Astrocytoma
Mutation
World Health Organization
Isocitrate Dehydrogenase
Astrocytoma
Mutation
World Health Organization
DeCS Terms
Enfoque GRADE
Neoplasias Encefálicas
Manipulación Quiropráctica
Quimioterapia Combinada
Neoplasias Encefálicas
Manipulación Quiropráctica
Quimioterapia Combinada
CIE Terms
Keywords
Astrocytoma, Guideline, IDH mutation, Low-grade glioma, Neuro-oncology, Oligodendroglioma
Citation
Vaz-Salgado MÁ, García BC, Pérez IF, Munárriz BJ, Domarco PS, González AH, et al. SEOM-GEINO clinical guidelines for grade 2 gliomas (2023). Clin Transl Oncol. 2024 Nov;26(11):2856-2865